Format

Send to

Choose Destination
J Oncol Research. 2017;1(1). pii: 101. Epub 2017 Oct 20.

National Institute on Aging /Alzheimer's Association criteria for Mild Cognitive Impairment applied to chemotherapy treated breast cancer survivors.

Author information

1
Wake Forest School of Medicine, Winston-Salem, USA.
2
Michigan CCOP, St. Mary's of Michigan, Saginaw, USA.
3
Upstate Carolina CCOP, Spartanburg, USA.
4
St. Vincent CCOP, Green Bay Oncology, Green Bay, WI.
5
Southeast Cancer Control Consortium, Cancer Center of WNC, Asheville, USA.
6
Medical College of Georgia MBCCOP, Augusta.

Abstract

Background:

In this analysis we use the National Institute on Aging/Alzheimer's Association (NIA/AA) criteria to identify Mild Cognitive Impairment (MCI) in a sample of breast cancer survivors treated with chemotherapy.

Methods:

Sixty women ages 39-79 on a prospective clinical trial of donepezil were assessed at baseline using a battery of standardized/validated neurocognitive measures. Cognitive status was adjudicated to identify MCI by a panel of dementia experts.

Results:

Fifty percent were not cognitively impaired, 43% met the NIA/AA criteria for MCI, 2% had dementia, and 5% could not be classified.

Discussion:

In this sample, nearly half of breast cancer survivors met the NIA/AA criteria for MCI. We propose these criteria be used to define cancer-related Mild Cognitive Impairment (cMCI), providing a framework for conducting additional studies to further characterize cMCI and identify clinical, imaging, and genetic factors associated with the progression of cMCI to more advanced stages of cognitive impairment.

KEYWORDS:

Breast cancer; Chemotherapy; Dementia; Mild Cognitive Impairment; Quality of life; Survivorship

PMID:
29873324
PMCID:
PMC5985141

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center